<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330042</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#00010949</org_study_id>
    <nct_id>NCT02330042</nct_id>
  </id_info>
  <brief_title>OCT Biomarkers for Diabetic Retinopathy</brief_title>
  <official_title>Functional Optical Coherence Tomography-Derived Biomarkers for Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <brief_summary>
    <textblock>
      Diabetic retinopathy (DR) is caused by changes in the blood vessels of the retina associated&#xD;
      with long-term Type 1 or Type 2 diabetes mellitus. DR is a leading cause of blindness in the&#xD;
      United States. Standard optical coherence tomography (OCT) cannot directly detect vascular&#xD;
      changes, which may occur early affecting the passage of blood through the tiny capillaries&#xD;
      (reduced capillary flow) or cause the greatest damage through formation of abnormal blood&#xD;
      vessel growth (neovascularization). Currently, fluorescein angiography (FA) is the gold&#xD;
      standard for detecting these changes, but FA requires an injection of a dye into the vein of&#xD;
      the arm of the patient. This dye can cause undesirable side effects. Recently, OCT has been&#xD;
      used to make functional measurements (such as total retinal blood flow among others) and to&#xD;
      perform angiography. Thus, functional OCT may provide a useful, alternate way to evaluate&#xD;
      diabetic retinopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with decreased total retinal blood flow by OCT angiography</measure>
    <time_frame>1 year</time_frame>
    <description>Total retinal blood flow will be measured in uL/min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with capillary dropout and/or new abnormal retinal blood vessel growth by OCT angiography</measure>
    <time_frame>1 year</time_frame>
    <description>Neovascular membrane area will be measured in mm2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with measureable macular edema by OCT imaging</measure>
    <time_frame>1 year</time_frame>
    <description>Retinal thickening area will be measured in mm2.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">165</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients with:&#xD;
Type 1 or Type 2 diabetes mellitus&#xD;
severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients with:&#xD;
Type 1 or Type 2 diabetes mellitus&#xD;
with or without mild to moderate NPDR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (controls)</arm_group_label>
    <description>Patients without diabetes or evidence of any form of eye disease</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Type 1 diabetes of greater than 5 years duration OR Type 2 diabetes of&#xD;
        any duration. Healthy controls are also being enrolled in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for participants with diabetes:&#xD;
&#xD;
          -  Male or female participants 18-79 years old&#xD;
&#xD;
          -  With Type 1 diabetes for over 5 years or Type 2 diabetes of any duration&#xD;
&#xD;
        Exclusion Criteria for participants with diabetes:&#xD;
&#xD;
          -  Vision worse than 20/200&#xD;
&#xD;
          -  Inability to maintain fixation for OCT imaging&#xD;
&#xD;
          -  Significant kidney disease, kidney failure or kidney transplant&#xD;
&#xD;
          -  Unstable medical status, including blood pressure greater than 180/110 or unstable&#xD;
             heart disease&#xD;
&#xD;
          -  Pregnant or nursing an infant&#xD;
&#xD;
          -  Presence of an eye disease (other than diabetic retinopathy) that can affect retinal&#xD;
             blood flow, retinal permeability or retinal anatomy&#xD;
&#xD;
          -  Significant cataract, corneal scar, vitreous bleed or other media opacity&#xD;
&#xD;
          -  History of major eye surgery within 4 months prior to enrollment in this study&#xD;
&#xD;
        Inclusion Criteria for participants without diabetes (controls):&#xD;
&#xD;
          -  Male or female participants 18-79 years old&#xD;
&#xD;
        Exclusion Criteria for participants without diabetes (controls):&#xD;
&#xD;
          -  Vision worse than 20/200&#xD;
&#xD;
          -  Inability to maintain fixation for OCT imaging&#xD;
&#xD;
          -  Significant kidney disease, kidney failure or kidney transplant&#xD;
&#xD;
          -  Unstable medical status, including blood pressure greater than 180/110 or unstable&#xD;
             heart disease&#xD;
&#xD;
          -  Pregnant or nursing an infant&#xD;
&#xD;
          -  Presence of any eye disease that can affect retinal blood flow, retinal permeability&#xD;
             or retinal anatomy&#xD;
&#xD;
          -  Significant cataract, corneal scar, vitreous bleed or other media opacity&#xD;
&#xD;
          -  History of major eye surgery within 4 months prior to enrollment in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2015</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>David Huang</investigator_full_name>
    <investigator_title>Yali Jia, PhD, Research Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>OCT</keyword>
  <keyword>Angiography</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

